المؤلفون: Hirayama AV; Clinical Research Division Fred Hutchinson Cancer Center Seattle Washington USA.; Department of Medicine University of Washington Seattle Washington USA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center Seattle Washington USA., Wright JH; Clinical Research Division Fred Hutchinson Cancer Center Seattle Washington USA., Smythe KS; Translational Science and Therapeutics Division Fred Hutchinson Cancer Center Seattle Washington USA., Fiorenza S; Clinical Research Division Fred Hutchinson Cancer Center Seattle Washington USA.; Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia., Shaw AN; Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia., Gauthier J; Clinical Research Division Fred Hutchinson Cancer Center Seattle Washington USA.; Department of Medicine University of Washington Seattle Washington USA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center Seattle Washington USA., Maloney DG; Department of Medicine University of Washington Seattle Washington USA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center Seattle Washington USA.; Translational Science and Therapeutics Division Fred Hutchinson Cancer Center Seattle Washington USA., Naresh KN; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center Seattle Washington USA.; Translational Science and Therapeutics Division Fred Hutchinson Cancer Center Seattle Washington USA.; Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA., Yeung CCS; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center Seattle Washington USA.; Translational Science and Therapeutics Division Fred Hutchinson Cancer Center Seattle Washington USA.; Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA., Turtle CJ; Department of Medicine University of Washington Seattle Washington USA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center Seattle Washington USA.; Translational Science and Therapeutics Division Fred Hutchinson Cancer Center Seattle Washington USA.; Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia.

المصدر: HemaSphere [Hemasphere] 2024 Aug 07; Vol. 8 (8), pp. e142. Date of Electronic Publication: 2024 Aug 07 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

المؤلفون: Pullarkat S; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Black G; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Bleakley M; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Pediatrics, University of Washington, Seattle, Washington, United States of America.; Program in Immunology, University of Washington, Seattle, Washington, United States of America., Buenrostro D; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Program in Immunology, University of Washington, Seattle, Washington, United States of America., Chapuis AG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Program in Immunology, University of Washington, Seattle, Washington, United States of America.; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States of America., Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States of America., Jaeger-Ruckstuhl CA; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Kimble EL; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States of America., Lee BM; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Maloney DG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States of America., Radich J; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Seaton BW; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Specht JM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States of America., Turtle CJ; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States of America.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA, United States of America., Woolston DW; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Wright JH; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Program in Immunology, University of Washington, Seattle, Washington, United States of America., Yeung CCS; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, United States of America.

المصدر: PloS one [PLoS One] 2024 Jun 06; Vol. 19 (6), pp. e0303057. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Formaldehyde* , Hepatitis B Virus, Woodchuck*/genetics , Receptors, Antigen, T-Cell*/genetics , Receptors, Antigen, T-Cell*/metabolism , Receptors, Antigen, T-Cell*/immunology, Humans ; Receptors, Chimeric Antigen/genetics ; Receptors, Chimeric Antigen/metabolism ; Receptors, Chimeric Antigen/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Tissue Fixation/methods ; Immunotherapy, Adoptive/methods ; Real-Time Polymerase Chain Reaction/methods

المؤلفون: Wang M; The University of Texas MD Anderson Cancer Center, Houston, TX., Siddiqi T; City of Hope National Medical Center, Duarte, CA., Gordon LI; Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL., Kamdar M; University of Colorado Cancer Center, Aurora, CO., Lunning M; University of Nebraska Medical Center, Omaha, NE., Hirayama AV; Fred Hutchinson Cancer Center, Seattle, WA., Abramson JS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Arnason J; Beth Israel Deaconess Medical Center, Boston, MA., Ghosh N; Atrium Health, Levine Cancer Institute, Charlotte, NC., Mehta A; University of Alabama at Birmingham, Birmingham, AL., Andreadis C; University of California, San Francisco, San Francisco, CA., Solomon SR; Northside Hospital Cancer Institute, Atlanta, GA., Kostic A; Bristol Myers Squibb, Seattle, WA., Dehner C; Bristol Myers Squibb, Seattle, WA., Espinola R; Bristol Myers Squibb, San Diego, CA., Peng L; Bristol Myers Squibb, Seattle, WA., Ogasawara K; Bristol Myers Squibb, Princeton, NJ., Chattin A; Bristol Myers Squibb, Seattle, WA., Eliason L; Bristol Myers Squibb, Princeton, NJ., Palomba ML; Memorial Sloan Kettering Cancer Center, New York, NY.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 01; Vol. 42 (10), pp. 1146-1157. Date of Electronic Publication: 2023 Dec 10.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Lymphoma, Large B-Cell, Diffuse*/drug therapy , Lymphoma, Mantle-Cell* , Neutropenia*/chemically induced, Adult ; Aged ; Humans ; Immunotherapy, Adoptive/adverse effects ; Neoplasm Recurrence, Local/drug therapy

المؤلفون: Banerjee R; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Poh C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Cowan AJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Till BG; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Green DJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Kiem HP; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Gopal AK; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.

المصدر: Blood advances [Blood Adv] 2024 Feb 27; Vol. 8 (4), pp. 895-898.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Receptors, Chimeric Antigen* , Neoplasms*/etiology , Neoplasms*/therapy , Physicians*, Humans ; Immunotherapy, Adoptive/adverse effects

المؤلفون: Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Kimble EL; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Wright JH; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Fiorenza S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA., Voutsinas JM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Wu Q; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA., Yeung CCS; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA., Gazeau N; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Pender BS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Kirchmeier DR; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Torkelson A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Chutnik AN; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Chapuis AG; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Green DJ; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Kiem HP; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Milano F; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA., Till BG; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Riddell SR; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Maloney DG; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Turtle CJ; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.

المصدر: Blood advances [Blood Adv] 2024 Jan 23; Vol. 8 (2), pp. 453-467.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy, Adoptive*/adverse effects , Immunotherapy, Adoptive*/methods , Lymphoma, Large B-Cell, Diffuse*/therapy , Lymphoma, Large B-Cell, Diffuse*/etiology, Adult ; Humans ; B7-H1 Antigen ; Cytokine Release Syndrome/etiology ; Immunotherapy

المؤلفون: Hirayama AV; Fred Hutchinson Cancer Center., Bleakley M; Fred Hutchinson Cancer Center.

المصدر: Blood [Blood] 2024 Jan 18; Vol. 143 (3), pp. 190-192.

نوع المنشور: Editorial; Comment

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized* , Therapeutic Index*

المؤلفون: Yeung CCS; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA., Woolston DW; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Wu V; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Voutsinas JM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Basom R; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Davis C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Hirayama AV; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA., Naresh KN; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

المصدر: European journal of haematology [Eur J Haematol] 2024 Jan; Vol. 112 (1), pp. 111-121. Date of Electronic Publication: 2023 Aug 01.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Receptors, Chimeric Antigen*/genetics , Cytopenia*, Humans ; Bone Marrow ; Neoplasm Recurrence, Local ; Immunotherapy ; Immunotherapy, Adoptive/adverse effects ; Cell- and Tissue-Based Therapy ; Antigens, CD19

المؤلفون: Liang EC; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Albittar A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Huang JJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Kimble EL; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Portuguese AJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Chapuis A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Till BG; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Milano F; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Kiem HP; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Turtle CJ; Faculity of Medicine and Health, University of Sydney, Sydney, Australia., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.

المصدر: Blood advances [Blood Adv] 2023 Nov 28; Vol. 7 (22), pp. 6990-7005.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Lymphocytic, Chronic, B-Cell*/etiology , Lymphoma, B-Cell* , Receptors, Chimeric Antigen*, Humans ; Antigens, CD19 ; Immunotherapy, Adoptive/methods ; Receptors, Antigen, T-Cell/genetics

المؤلفون: Gazeau N; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Hematology Service, Centre Hospitalier Universitaire de Lille, Lille, France., Liang EC; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Wu QV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Voutsinas JM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Barba P; Hematology Department, Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain., Iacoboni G; Hematology Department, Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain., Kwon M; Department of Hematology, Hospital General Universitario Gregrorio Marañon, Institute of Health Research Gregorio Marañon. Universidad Complutense de Madrid, Madrid, Spain., Ortega JLR; Hematology Service, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Sevilla, Spain., López-Corral L; Hematology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Centro de Investigación del Cáncer-IBMCC, Spain., Hernani R; Hematology Department, Hospital Clinico Universitario, INCLIVA Research Institut, Valencia, Spain., Ortiz-Maldonado V; Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain., Martínez-Cibrian N; Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain., Martinez AP; Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain., Maziarz RT; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Williamson S; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Nemecek ER; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Cowan AJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Green DJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Kimble E; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Turtle CJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington. Electronic address: jgauthier@fredhutch.org.

المصدر: Transplantation and cellular therapy [Transplant Cell Ther] 2023 Jul; Vol. 29 (7), pp. 430-437. Date of Electronic Publication: 2023 Apr 07.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE

مواضيع طبية MeSH: Receptors, Chimeric Antigen*, Humans ; Interleukin 1 Receptor Antagonist Protein/adverse effects ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/etiology ; Prospective Studies ; Retrospective Studies ; Plasma Cells ; Ferritins ; Cell- and Tissue-Based Therapy

المؤلفون: Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Chou CK; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, WA., Miyazaki T; Nektar Therapeutics, San Francisco, CA., Steinmetz RN; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Di HA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Fraessle SP; Institute for Medical Microbiology Immunology and Hygiene, Technical University of Munich, Munich, Germany., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Fiorenza S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA., Hawkins RM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Overwijk WW; Nektar Therapeutics, San Francisco, CA., Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Marcondes MQ; Nektar Therapeutics, San Francisco, CA., Turtle CJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.

المصدر: Blood advances [Blood Adv] 2023 Jun 13; Vol. 7 (11), pp. 2479-2493.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Interleukin-15* , Receptors, Antigen, T-Cell*, Humans ; Animals ; Mice ; Neoplasm Recurrence, Local ; T-Lymphocytes ; Immunotherapy ; Antigens, CD19